CYP2C19 and obesity disorder: A recent research suggested that CYP2C19 activity is lower in patients with obesity versus nonobese controls and increased following RYGB-induced weight loss by measuring the plasma (3 h) 5-hydroxyomeprazole (5-OH-omeprazole)/omeprazole ratio [29].